《大行報告》瑞信下調潤啤(00291.HK)目標價至76元 評級「跑贏大市」
瑞信發表報告指,華潤啤酒(00291.HK)去年收入、經常性EBIT及經常性利潤分別為333.87億元、46.52億元及35.83億元人民幣,按年增長6%、22%及35%。撇除資產減值等稅項調整開支,預期集團去年經常性利潤為36.8億元人民幣,較預期中間值低3%。
瑞信下調潤啤股份目標價,由84元降至76元,評級維持「跑贏大市」,並調低集團今明兩年盈利預測分別10%及8%,以反映毛利率下降及一次性項目的稅項調整。該行仍對潤啤的長期高檔化前景看法正面,預期集團2021年至2023年的EBITDA及純利年均複合增長率達23%及30%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.